Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Shares Sold by Thrivent Financial for Lutherans

Thrivent Financial for Lutherans lowered its position in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 10.4% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 23,655 shares of the company’s stock after selling 2,747 shares during the period. Thrivent Financial for Lutherans’ holdings in Harmony Biosciences were worth $946,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in the company. nVerses Capital LLC acquired a new stake in shares of Harmony Biosciences during the 2nd quarter worth about $36,000. CWM LLC raised its stake in shares of Harmony Biosciences by 111.7% in the 3rd quarter. CWM LLC now owns 1,469 shares of the company’s stock valued at $59,000 after acquiring an additional 775 shares during the period. Quarry LP acquired a new position in shares of Harmony Biosciences in the 2nd quarter worth approximately $62,000. Headlands Technologies LLC boosted its position in shares of Harmony Biosciences by 1,608.1% during the 2nd quarter. Headlands Technologies LLC now owns 2,545 shares of the company’s stock worth $77,000 after purchasing an additional 2,396 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in Harmony Biosciences by 21.2% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,056 shares of the company’s stock valued at $80,000 after purchasing an additional 360 shares during the last quarter. Hedge funds and other institutional investors own 86.23% of the company’s stock.

Harmony Biosciences Trading Up 1.3 %

Shares of HRMY stock opened at $35.13 on Tuesday. The company has a market capitalization of $2.00 billion, a P/E ratio of 16.65, a price-to-earnings-growth ratio of 0.64 and a beta of 0.77. The company has a current ratio of 3.24, a quick ratio of 3.20 and a debt-to-equity ratio of 0.28. The business’s 50 day moving average is $35.09 and its two-hundred day moving average is $33.79. Harmony Biosciences Holdings, Inc. has a twelve month low of $28.14 and a twelve month high of $41.61.

Harmony Biosciences (NASDAQ:HRMY) last announced its quarterly earnings data on Tuesday, October 29th. The company reported $0.79 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.64 by $0.15. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. The company had revenue of $186.00 million for the quarter, compared to analysts’ expectations of $184.07 million. During the same period in the previous year, the company posted $0.63 EPS. Harmony Biosciences’s revenue was up 16.0% compared to the same quarter last year. Equities analysts forecast that Harmony Biosciences Holdings, Inc. will post 2.36 EPS for the current year.

Insider Buying and Selling at Harmony Biosciences

In other news, insider Jeffrey Dierks sold 21,496 shares of the firm’s stock in a transaction that occurred on Tuesday, October 29th. The stock was sold at an average price of $40.47, for a total value of $869,943.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 30.80% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

HRMY has been the topic of several research analyst reports. UBS Group assumed coverage on Harmony Biosciences in a report on Tuesday, September 10th. They issued a “buy” rating and a $56.00 price objective on the stock. Cantor Fitzgerald upped their price objective on Harmony Biosciences from $51.00 to $58.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 30th. Mizuho lifted their price objective on Harmony Biosciences from $42.00 to $52.00 and gave the company an “outperform” rating in a research note on Thursday, October 10th. Raymond James reissued an “outperform” rating and set a $40.00 price objective on shares of Harmony Biosciences in a research report on Thursday, October 10th. Finally, Oppenheimer reaffirmed an “outperform” rating and issued a $59.00 target price (up previously from $56.00) on shares of Harmony Biosciences in a report on Wednesday, October 30th. Two analysts have rated the stock with a sell rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $47.00.

Harmony Biosciences Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.